Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy
dc.contributor.author | Wheeler, Matthew T. | |
dc.contributor.author | Jacoby, Daniel | |
dc.contributor.author | Elliott, Perry M. | |
dc.contributor.author | Saberi, Sara | |
dc.contributor.author | Hegde, Sheila M. | |
dc.contributor.author | Lakdawala, Neal K. | |
dc.contributor.author | Myers, Jonathan | |
dc.contributor.author | Sehnert, Amy J. | |
dc.contributor.author | Edelberg, Jay M. | |
dc.contributor.author | Li, Wanying | |
dc.contributor.author | Olivotto, Iacopo | |
dc.date.accessioned | 2023-03-03T21:08:34Z | |
dc.date.available | 2024-03-03 16:08:33 | en |
dc.date.available | 2023-03-03T21:08:34Z | |
dc.date.issued | 2023-02 | |
dc.identifier.citation | Wheeler, Matthew T.; Jacoby, Daniel; Elliott, Perry M.; Saberi, Sara; Hegde, Sheila M.; Lakdawala, Neal K.; Myers, Jonathan; Sehnert, Amy J.; Edelberg, Jay M.; Li, Wanying; Olivotto, Iacopo (2023). "Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy." European Journal of Heart Failure 25(2): 260-270. | |
dc.identifier.issn | 1388-9842 | |
dc.identifier.issn | 1879-0844 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175888 | |
dc.description.abstract | AimsIn the EXPLORER-HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart Association (NYHA) class, were greater in patients not receiving background beta-blockers than in those receiving beta-blockers. We sought to determine if the effect of background treatment was consistent across other clinically meaningful parameters.Methods and resultsSubgroup analyses by beta-blocker use were performed in patients with oHCM from the EXPLORER-HCM and mavacamten long-term extension (MAVA-LTE) studies. In EXPLORER-HCM, 189 patients (75.3%) were receiving beta-blockers, and 62 (24.7%) were receiving non-dihydropyridine calcium channel blockers or no background HCM medication; 170 patients (90.4%) receiving beta-blockers had chronotropic incompetence. Improvements in peak VO2 at week 30 with mavacamten versus placebo were lower with beta-blockers (mean difference [95% confidence interval (CI)]: 1.04 [0.12, 1.95] ml/kg/min) than without beta-blockers (mean difference [95% CI]: 2.69 [1.29, 4.09] ml/kg/min); improvements in non-heart rate-dependent parameters (VE/VCO2 slope) appeared unaffected by beta-blockers. Improvements in functional capacity parameters at week 30 with mavacamten versus placebo were independent of beta-blockade for post-exercise left ventricular outflow tract gradient (mean difference [95% CI]: −37.9 [−48.0, −27.9] mmHg with beta-blockers; −33.5 [−53.6, −13.3] mmHg without beta-blockers), proportion of patients with reduction of ≥1 NYHA class, Kansas City Cardiomyopathy Questionnaire clinical summary scores and N-terminal pro-B-type natriuretic peptide. Mavacamten benefits were reproduced and maintained in MAVA-LTE regardless of beta-blockade.ConclusionMavacamten improved measures of functional capacity, left ventricular outflow tract obstruction, symptom burden and biomarkers in patients with HCM regardless of beta-blocker use. Beta-blocker use was often associated with chronotropic incompetence, affecting peak VO2 and other heart rate-dependent measures, but had minimal impact on heart rate-independent measures.Summary of the effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy in the EXPLORER-HCM and MAVA-LTE studies. Mavacamten confers overall benefit in patients with obstructive hypertrophic cardiomyopathy irrespective of background beta-blockade. HR, heart rate; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire clinical summary score; LVOT, left ventricular outflow tract; MET, metabolic equivalent; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; VE/VCO2, minute ventilation to carbon dioxide production; VO2, oxygen consumption. | |
dc.publisher | John Wiley & Sons, Ltd. | |
dc.subject.other | Exercise capacity | |
dc.subject.other | Beta-blockers | |
dc.subject.other | Obstructive hypertrophic cardiomyopathy | |
dc.subject.other | Mavacamten | |
dc.subject.other | Symptoms | |
dc.title | Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Cardiovascular Medicine | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175888/1/ejhf2737.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175888/2/ejhf2737_am.pdf | |
dc.identifier.doi | 10.1002/ejhf.2737 | |
dc.identifier.source | European Journal of Heart Failure | |
dc.identifier.citedreference | January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130: e199 – 267. | |
dc.identifier.citedreference | Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020; 75: 2649 – 60. | |
dc.identifier.citedreference | Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000; 35: 1245 – 55. | |
dc.identifier.citedreference | Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 76: 2379 – 90. | |
dc.identifier.citedreference | Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020; 76: 3022 – 55. | |
dc.identifier.citedreference | Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35: 2733 – 79. | |
dc.identifier.citedreference | Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018; 379: 655 – 68. | |
dc.identifier.citedreference | Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993; 21: 1672 – 9. | |
dc.identifier.citedreference | Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021; 78: 2505 – 17. | |
dc.identifier.citedreference | Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017; 292: 16571 – 7. | |
dc.identifier.citedreference | Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016; 351: 617 – 21. | |
dc.identifier.citedreference | Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 396: 759 – 69. | |
dc.identifier.citedreference | Van Baak MA. Beta-adrenoceptor blockade and exercise. An update. Sports Med. 1988; 5: 209 – 25. | |
dc.identifier.citedreference | Palau P, Seller J, Domínguez E, Sastre C, Ramón JM, de La Espriella R, et al. Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol. 2021; 78: 2042 – 56. | |
dc.identifier.citedreference | Smarz K, Tysarowski M, Zaborska B, Pilichowska-Paszkiet E, Sikora-Frac M, Budaj A, et al. Chronotropic incompetence limits aerobic exercise capacity in patients taking beta-blockers: real-life observation of consecutive patients. Healthcare (Basel). 2021; 9: 212. | |
dc.identifier.citedreference | Ho CY, Olivotto I, Jacoby D, Lester SJ, Roe M, Wang A, et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail. 2020; 13: e006853. | |
dc.identifier.citedreference | Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124: 2761 – 96. | |
dc.identifier.citedreference | Efthimiadis GK, Giannakoulas G, Parcharidou DG, Pagourelias ED, Kouidi EJ, Spanos G, et al. Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy. Int J Cardiol. 2011; 153: 179 – 84. | |
dc.identifier.citedreference | Nambiar L, Meyer M. β-Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction: recommendations, mechanisms, and concerns. Coron Artery Dis. 2018; 29: 262 – 70. | |
dc.identifier.citedreference | Peyracchia M, Errigo D, Raposeiras Rubin S, Conrotto F, DiNicolantonio JJ, Omedè P, et al. Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results. J Cardiovasc Med. 2018; 19: 337 – 43. | |
dc.identifier.citedreference | Kloner RA, Chaitman B. Angina and its management. J Cardiovasc Pharmacol Ther. 2017; 22: 199 – 209. | |
dc.identifier.citedreference | Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018; 138: e210 – 71. | |
dc.identifier.citedreference | Seller J, Palau P, Domínguez E, Sastre C, Larumbe A, Ramón JM, et al. Effect on maximal functional capacity of beta-blockers withdrawal in heart failure with preserved ejection fraction and chronotropic incompetence: PRESERVE-HR trial. European Society of Cardiology Heart Failure; 2021. https://www.slideshare.net/casadelcorazon/preservehr-trial | |
dc.identifier.citedreference | Magrì D, Santolamazza C. Cardiopulmonary exercise test in hypertrophic cardiomyopathy. Ann Am Thorac Soc 2017; 14 (Suppl 1 ): S102 – 9. | |
dc.identifier.citedreference | Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. The ventilatory classification system effectively predicts hospitalization in patients with heart failure. J Cardiopulm Rehabil Prev. 2008; 28: 195 – 8. | |
dc.identifier.citedreference | Arena R, Myers J, Abella J, Peberdy MA, Bensimhon D, Chase P, et al. Development of a ventilatory classification system in patients with heart failure. Circulation. 2007; 115: 2410 – 7. | |
dc.identifier.citedreference | Francis DP, Shamim W, Davies LC, Piepoli MF, Ponikowski P, Anker SD, et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO 2 slope and peak VO 2. Eur Heart J. 2000; 21: 154 – 61. | |
dc.identifier.citedreference | Dimopoulos K, Okonko DO, Diller GP, Broberg CS, Salukhe TV, Babu-Narayan SV, et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation. 2006; 113: 2796 – 802. | |
dc.identifier.citedreference | Bard RL, Gillespie BW, Clarke NS, Egan TG, Nicklas JM. Determining the best ventilatory efficiency measure to predict mortality in patients with heart failure. J Heart Lung Transplant. 2006; 25: 589 – 95. | |
dc.identifier.citedreference | Klaassen SHC, Liu LCY, Hummel YM, Damman K, van der Meer P, Voors AA, et al. Clinical and hemodynamic correlates and prognostic value of VE/VCO 2 slope in patients with heart failure with preserved ejection fraction and pulmonary hypertension. J Card Fail. 2017; 23: 777 – 82. | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.